Up to 12.5% of the US population is affected by chronic rhinosinusitus, including this woman blowing her nose.

Chronic rhinosinusitis (CRS), inflammation of the paranasal sinuses and lining of the nasal cavity for 12 weeks or more, affects up to 12.5% of the U.S. population and has a significant disease burden. CRS patients visit primary care physicians twice as often as those without the disease and have five times as many prescriptions filled.

Based on national ambulatory data, rhinosinusitis accounts for more outpatient antibiotic prescriptions than any other diagnosis. The annual total direct and indirect cost of CRS exceeds $12 billion. 

Sino-Nasal Outcome Test

Created in 1992 by Dr. Piccirillo, the Sino-Nasal Outcome Test (SNOT) is now used across the world as a measure of rhinosinusitis health status and quality of life.

The SNOT has been validated internationally, and cited in the literature more than 1,000 times. It is used in more than 35 countries and has been translated into more than 50 languages and dialects.

Sino-Nasal Outcome Test (SNOT) »

SNOT is available in 50 languages. See the list »

Learn how to license the SNOT instrument »

Publications

The use of Sino-Nasal Outcome Test (SNOT) instrument in quality improvement programs for patients with chronic rhinosinusitis by Jay Piccirillo, MD »